Lisata Therapeutics, Inc.

welcome to the lasada therapeutics full year 2023 financial results and business update conference call currently all participants are in a listen-only mode following management's prepared remarks we'll hold the q a session to ask a question at that time please press star 1 1 on your telephone you will then hear an automated message advising your hand is raised as a reminder this call is being recorded today february 29 2024. i will now turn the call over to john mendito Vice President of Investor Relations and Corporate Communications at La Sada. Please go ahead, sir.

Thank you, operator, and good afternoon, everyone. Welcome to La Sada's full year 2023 conference call to discuss our financial results and provide a business update. Joining me today from our management team are Dr. David Mazzo, President and Chief Executive Officer, Dr. Kristen Buck, Executive Vice President of Research and Development and Chief Medical Officer, and James Nisko, Vice President of Finance and Treasury. Shortly before this call, we issued a press release announcing our full year 2023 financial results, which is available under the Investors and News section of the company website, along with the webcast replay of this call. If you have not received this news release, or if you'd like to be added to the company's email distribution list, please email me at jmendito at lasada.com. Before we begin, I remind you that comments made by management during this conference call will contain forward-looking statements that involve risks and uncertainties regarding the operations and future results of LISADA. I encourage you to review the company's filings with the Securities and Exchange Commission, including, without limitation, its forms 10-Q, 8-K, and 10-K, which identify specific risk factors that may cause actual results or events to differ materially from those described in the forward-looking statements. Furthermore, the content of this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, Thursday, February 29th, 2024. La Sada Therapeutics undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this conference call. With that, I will now turn the call over to Dr. Mazzo. Dave?

Thank you, John, and good afternoon, everyone. Thank you for joining us today as we provide an overview of recent business highlights, discuss our full year 2023 financial results, and give an update on the progress of our various development programs. During 2023, our first full year as Lasada, we made notable progress advancing our clinical development programs, targeting several advanced solid tumors using ListaOne, our lead product candidate, in combination with multiple anti-cancer agents of differing modalities. As we have previously reported, we have both preclinical and early clinical data in humans that we believe demonstrates the potential of LISTA-1 to become an integral part of a revised standard of care treatment regimen for many difficult-to-treat cancers. Following the review of the financial results, Lasada's Chief Medical Officer, Dr. Kristen Buck, will provide an update on our ongoing and planned clinical programs. With that, I now will turn the call over to James Nisko, our Vice President of Finance and Treasury. James?